Analysts think NRXP stock price could increase by 2513%
Oct 25, 2024, 11:25 AM
4.13%
What does NRXP do
NRX Pharmaceuticals, headquartered in Wilmington, Delaware, is a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, including its lead compounds NRX-100 and NRX-101. The company went public on November 20, 2017, and is developing therapies targeting bipolar depression, chronic pain, and PTSD.
5 analysts think NRXP stock price will increase by 2513.22%. The current median analyst target is $31.62 compared to a current stock price of $1.21. The lowest analysts target is $19.19 and the highest analyst target is $46.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
